Study designs of evaluations included in the review
Randomised controlled trials (RCTs) with at least 6 months’ follow-up were eligible for inclusion.
Specific interventions included in the review
Studies were eligible for inclusion if they compared pioglitazone or rosiglitazone, added to standard therapy, with other antidiabetic drugs in people with diabetes, or with no antidiabetic therapy in people without diabetes. Studies assessing troglitazone were excluded. In the included studies, treatment was started either prior to PCI or up to 2 weeks post-PCI. The dose for pioglitazone was 30 mg daily, and for rosiglitazone 4 mg daily. Bare metal and drug-eluting stents from nine different manufacturers were used.
Participants included in the review
Studies on people undergoing PCI were eligible for inclusion. Four of the 5 included studies were on people with diabetes; the remaining study was on people without diabetes. In addition, where stated, people also had acute coronary syndrome, acute myocardial infarction (MI), unstable angina or exercise-induced ischaemia.
Outcomes assessed in the review
Studies had to have assessed outcomes using quantitative coronary angiography at 6 months or longer. The primary outcomes were rate of restenosis (defined as more than 50% of target lesion), percentage diameter stenosis and in-stent minimum lumen diameter. The secondary outcomes included rates of target lesion revascularisation, MI, mortality and drug side-effects.
How were decisions on the relevance of primary studies made?
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.